Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

Synthesis, characterization, conformational analysis of a cyclic conjugated octreotate peptide and biological evaluation of (99m)Tc-HYNIC-His(3)-Octreotate as novel tracer for the imaging of somatostatin receptor-positive tumors.

Behera A, Banerjee I, De K, Munda RN, Chattopadhayay S, Samanta A, Sarkar B, Ganguly S, Misra M.

Amino Acids. 2013 Mar;44(3):933-46. doi: 10.1007/s00726-012-1423-7. Epub 2012 Oct 23.

PMID:
23090293
3.

Radiolabeled new somatostatin analogs conjugated to DOMA chelator used as targeted tumor imaging agent: synthesis and radiobiological evaluation.

De K, Banerjee I, Misra M.

Amino Acids. 2015 Jun;47(6):1135-53. doi: 10.1007/s00726-015-1942-0. Epub 2015 Mar 6.

PMID:
25743164
4.
5.

[99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.

Decristoforo C, Faintuch-Linkowski B, Rey A, von Guggenberg E, Rupprich M, Hernandez-Gonzales I, Rodrigo T, Haubner R.

Nucl Med Biol. 2006 Nov;33(8):945-52.

PMID:
17127166
6.

[(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.

Maina T, Nock BA, Cordopatis P, Bernard BF, Breeman WA, van Gameren A, van den Berg R, Reubi JC, Krenning EP, de Jong M.

Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):831-40. Epub 2006 Mar 28.

PMID:
16568203
7.

(99m)Tc-labeled dimeric octreotide peptide: a radiotracer with high tumor uptake for single-photon emission computed tomography imaging of somatostatin receptor subtype 2-positive tumors.

Dong C, Zhao H, Yang S, Shi J, Huang J, Cui L, Zhong L, Jin X, Li F, Liu Z, Jia B, Wang F.

Mol Pharm. 2013 Aug 5;10(8):2925-33. doi: 10.1021/mp400040z. Epub 2013 Jun 28.

PMID:
23768172
8.

Synthesis, radiolabeling, and preclinical evaluation of a new octreotide analog for somatostatin receptor-positive tumor scintigraphy.

De K, Bhowmik A, Behera A, Banerjee I, Ghosh MK, Misra M.

J Pept Sci. 2012 Dec;18(12):720-30. doi: 10.1002/psc.2458. Epub 2012 Oct 26.

PMID:
23109400
9.

Preparation and biological evaluation of [(99m)Tc/EDDA/Tricine/HYNIC(0), BzThi(3)]-octreotide for somatostatin receptor-positive tumor imaging.

Erfani M, Shafiei M, Mazidi M, Goudarzi M.

Cancer Biother Radiopharm. 2013 Apr;28(3):240-7. doi: 10.1089/cbr.2012.1270. Epub 2013 Mar 6.

PMID:
23464855
10.
11.

Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies.

Faintuch BL, Teodoro R, Duatti A, Muramoto E, Faintuch S, Smith CJ.

Nucl Med Biol. 2008 May;35(4):401-11. doi: 10.1016/j.nucmedbio.2008.02.005.

PMID:
18482677
12.

Multimeric system of 99mTc-labeled gold nanoparticles conjugated to c[RGDfK(C)] for molecular imaging of tumor α(v)β(3) expression.

Morales-Avila E, Ferro-Flores G, Ocampo-García BE, De León-Rodríguez LM, Santos-Cuevas CL, García-Becerra R, Medina LA, Gómez-Oliván L.

Bioconjug Chem. 2011 May 18;22(5):913-22. doi: 10.1021/bc100551s. Epub 2011 May 3.

PMID:
21513349
13.

Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.

Ortiz-Arzate Z, Santos-Cuevas CL, Ocampo-García BE, Ferro-Flores G, García-Becerra R, Estrada G, Gómez-Argumosa E, Izquierdo-Sánchez V.

Nucl Med Commun. 2014 Apr;35(4):423-32. doi: 10.1097/MNM.0000000000000065.

PMID:
24335877
14.

Tetraamine-modified octreotide and octreotate: labeling with 99mTc and preclinical comparison in AR4-2J cells and AR4-2J tumor-bearing mice.

Nikolopoulou A, Maina T, Sotiriou P, Cordopatis P, Nock BA.

J Pept Sci. 2006 Feb;12(2):124-31.

PMID:
16059963
15.

Evaluation of 99mTc-labeled cyclic RGD dimers: impact of cyclic RGD peptides and 99mTc chelates on biological properties.

Zhou Y, Kim YS, Lu X, Liu S.

Bioconjug Chem. 2012 Mar 21;23(3):586-95. doi: 10.1021/bc200631g. Epub 2012 Mar 6.

16.

Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers.

Wang L, Shi J, Kim YS, Zhai S, Jia B, Zhao H, Liu Z, Wang F, Chen X, Liu S.

Mol Pharm. 2009 Jan-Feb;6(1):231-45. doi: 10.1021/mp800150r.

17.

99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours.

von Guggenberg E, Dietrich H, Skvortsova I, Gabriel M, Virgolini IJ, Decristoforo C.

Eur J Nucl Med Mol Imaging. 2007 Aug;34(8):1209-18. Epub 2007 Feb 17.

PMID:
17308920
18.

Isolation, characterization, and biological evaluation of syn and anti diastereomers of [(99m)Tc]technetium depreotide: a somatostatin receptor binding tumor imaging agent.

Cyr JE, Pearson DA, Nelson CA, Lyons BA, Zheng Y, Bartis J, He J, Cantorias MV, Howell RC, Francesconi LC.

J Med Chem. 2007 Sep 6;50(18):4295-303. Epub 2007 Aug 11.

19.
20.

Kit for preparation of multimeric receptor-specific ⁹⁹mTc-radiopharmaceuticals based on gold nanoparticles.

Ocampo-García B, Ferro-Flores G, Morales-Avila E, Ramírez Fde M.

Nucl Med Commun. 2011 Nov;32(11):1095-104. doi: 10.1097/MNM.0b013e32834acf33.

PMID:
21860334
Items per page

Supplemental Content

Write to the Help Desk